Literature DB >> 8695215

Quality of prostate cancer data in the cancer registry of Norway.

S Harvei1, S Tretli, F Langmark.   

Abstract

Completeness of reporting and internal validity of the coding of prostate cancer in the Cancer Registry (CR) in Norway were examined. Data were matched and evaluated against diagnostic indices at eight selected hospitals in the country and against death certificates from Statistics Norway. Validity control was based on detailed re-analysis of an approximately 1% sample of the registered data during the period 1957-1986. The deficiency in reporting of prostate cancer was less than 1%. The grave deficiencies in hospital patient registers were considered to be of non-systematic nature and should, therefore, not impair the reliability of our investigation of incompleteness. The validity control revealed errors in 0.5% of the data elements, or, illustrated differently, 6% of the patient files had an error, of importance or not, in one of the data elements. One false positive registration was found among 298 controlled patient files (0.3%).

Entities:  

Mesh:

Year:  1996        PMID: 8695215     DOI: 10.1016/0959-8049(95)00501-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

1.  Childhood central nervous system tumors and leukemia: Incidence and familial risk. A comparative population-based study in Utah and Norway.

Authors:  Ruby Del Risco Kollerud; Lisa A Cannon-Albright; Hege S Haugnes; Ellen Ruud; Magne Thoresen; Per Nafstad; Karl Gerhard Blaasaas; Øyvind Naess; Bjørgulf Claussen
Journal:  Pediatr Blood Cancer       Date:  2020-05-21       Impact factor: 3.167

2.  Age dependence of modern clinical risk groups for localized prostate cancer-A population-based study.

Authors:  Minh-Phuong Huynh-Le; Tor Åge Myklebust; Christine H Feng; Roshan Karunamuni; Tom Børge Johannesen; Anders M Dale; Ole A Andreassen; Tyler M Seibert
Journal:  Cancer       Date:  2020-01-03       Impact factor: 6.860

3.  Dairy consumption and calcium intake and risk of breast cancer in a prospective cohort: the Norwegian Women and Cancer study.

Authors:  Anette Hjartåker; Magne Thoresen; Dagrun Engeset; Eiliv Lund
Journal:  Cancer Causes Control       Date:  2010-07-25       Impact factor: 2.506

4.  Quality assessment of the registration of vulvar and vaginal premalignant lesions at the Cancer Registry of Norway.

Authors:  Espen Enerly; Freddie Bray; Christine Mellem; Bo Terning Hansen; Grete Kjølberg; Tove Dahl; Tom Børge Johannesen; Mari Nygård
Journal:  Acta Oncol       Date:  2011-11-02       Impact factor: 4.089

5.  An epidemiological study of cancer in adult twins born in Norway 1905-1945.

Authors:  T Iversen; S Tretli; E Kringlen
Journal:  Br J Cancer       Date:  2001-06-01       Impact factor: 7.640

6.  Socio-economic and lifestyle factors associated with the risk of prostate cancer.

Authors:  T I Lund Nilsen; R Johnsen; L J Vatten
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

7.  Detecting contaminated birthdates using generalized additive models.

Authors:  Wei Luo; Marcus Gallagher; Bill Loveday; Susan Ballantyne; Jason P Connor; Janet Wiles
Journal:  BMC Bioinformatics       Date:  2014-06-12       Impact factor: 3.169

8.  Is prostatic intraepithelial neoplasia in the transition/central zone a true precursor of cancer? A long-term retrospective study in Norway.

Authors:  S Harvei; F J Skjørten; T E Robsahm; A Berner; S Tretli
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

9.  Height, body mass index, and prostate cancer: a follow-up of 950000 Norwegian men.

Authors:  A Engeland; S Tretli; T Bjørge
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

10.  The incidence of renal cancer in Polish National Cancer Registry: is there any epidemiological data we can rely on?

Authors:  Piotr Zygmunt Wojcieszak; Sławomir Poletajew; Daniel Rutkowski; Piotr Radziszewski
Journal:  Cent European J Urol       Date:  2014-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.